Sunitinib decreases the expression of KRT6A and SERPINB1 in 3D human epidermal models. Issue 3 (17th November 2020)

• Record Type: Journal Article
• Authors: Yoshida, Ayaka; Yamamoto, Kazuhiro; Ishida, Takahiro; Omura, Tomohiro; Itoh, Tomoo; Nishigori, Chikako; Sakane, Toshiyasu; Yano, Ikuko
• Is Part Of: Experimental dermatology. Volume 30:Issue 3(2021)
• Page Start: 337
• Page End: 346
• Publication Date: 2020-11-17
• Subjects: 3D epidermal model -- foot skin reaction -- hand -- KRT6A -- SERPINB1 -- sunitinib; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/exd.14230
• Languages: English
• ISSNs: 0906-6705

Abstract

Abstract: Hand–foot skin reaction (HFSR) is a common side effect caused by several tyrosine kinase inhibitors, including sunitinib. However, the nature of the cornifying factors related to the molecular biological mechanisms underlying HFSR remains poorly understood. We used human keratinocyte models to investigate the key cornifying factors for dermatological and biological abnormalities induced by sunitinib. On the basis of the results of microarray analysis using the three‐dimensional (3D) human epidermal model, keratin (KRT)6A, serine protease inhibitor (SERPIN)B1, KRT5, and SERPIN Kazal‐type 6 were selected as candidate genes related to HFSR. Sunitinib treatment significantly decreased the expression of SERPINB1 and KRT6A in the immunohistochemical staining of the 3D epidermal model. In PSVK1 cells, but not in normal human epidermal keratinocyte cells, both of which are human normal keratinocyte cell lines, sunitinib decreased the expression of KRT6A with a concomitant decrease in levels of phosphorylated extracellular signal‐regulated kinases (ERK)1/2 and phosphorylated p38 mitogen‐activated protein kinase (MAPK). Inhibitors of the ERK and p38 MAPK signal pathways also significantly decreased KRT6A expression. Sunitinib‐induced decrease in KRT6A expression was suppressed by the inhibition of glycogen synthase kinase‐3β by enhancing ERK1/2 and p38 MAPK phosphorylation. Thus, sunitinib reduces the expression of KRT6A and SERPINB1 by inhibiting the ERK1/2 and p38 MAPK signalling pathways in the skin model. These changes in expression contribute to the pathology of HFSR.